<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03516851</url>
  </required_header>
  <id_info>
    <org_study_id>pkuihsw1</org_study_id>
    <nct_id>NCT03516851</nct_id>
  </id_info>
  <brief_title>Precision Bypass in Patients With Moyamoya Disease</brief_title>
  <acronym>PBM</acronym>
  <official_title>Multimodal Neuronavigation Guiding Precision Bypass in Adult Ischemic Patients With Moyamoya Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University International Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Tiantan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking University International Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Extracranial-intracranial arterial bypass, including anastomosis of the superficial temporal&#xD;
      artery to the middle cerebral artery and indirect bypass, can help prevent further ischaemic&#xD;
      attacks in patients with Moyamoya disease (MMD). However, there is no established standard&#xD;
      for the selection of the recipient vessels. In most situations, surgeons choose the recipient&#xD;
      vessels with their own experiences. Intraoperative Indocyanine green (ICG) angiography using&#xD;
      Flow800 software and multimodal neuronavigation can be used to assess the real-time cerebral&#xD;
      blood flow velocity and perfusion of local brain tissue for better selection of the recipient&#xD;
      vessels. Thus the aim of this study is to to determine whether direct bypass surgery combined&#xD;
      with multimodal neuronavigation is superior to traditional direct bypass procedure alone in&#xD;
      adult ischemic MMD patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There are no effective medical therapies for moyamoya disease. Through the provision of&#xD;
      collateral pathways, surgical revascularisation is the most successful therapy to improve&#xD;
      cerebral haemodynamics, and to reduce the risk of subsequent stroke. Surgical procedures for&#xD;
      moyamoya disease can be classified into three categories: direct bypass, indirect bypass, and&#xD;
      combined bypass. Although surgeons have their own experience choosing the recipient&#xD;
      vessels,no standard has been established based on a worldwide consensus.&#xD;
&#xD;
      Intraoperative ICG angiography using Flow800 software and multimodal neuronavigation&#xD;
      (structure combined with perfusion MRI sequence) can be used to assess the real-time cerebral&#xD;
      blood flow velocity and perfusion of local brain tissue, which is contribute to choose a&#xD;
      recipient vessels with relative low cerebral blood flow velocity and perfusion.&#xD;
&#xD;
      Therefore,the PBM study in our institution is designed to compare the direct bypass surgery&#xD;
      with multimodal neuronavigation with traditional direct bypass procedure alone in preventing&#xD;
      any ischemic event afterwards after cerebral revascularization surgery in adult ischemic MMD&#xD;
      patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    there are not enough participants enrolled&#xD;
  </why_stopped>
  <start_date type="Actual">August 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ischemic events</measure>
    <time_frame>30 days</time_frame>
    <description>All strokes &amp; death within 30 days post-surgery and ipsilateral infarctions afterwards</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>postoperative complications</measure>
    <time_frame>30 days</time_frame>
    <description>All kinds of adverse events related to surgery within 30 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infarctions</measure>
    <time_frame>1 years</time_frame>
    <description>Infarctions on the contralateral side within 1 year of randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transient ischemic attack (TIA)</measure>
    <time_frame>1 years</time_frame>
    <description>Transient ischemic attack on the surgically treated side within 1 year of randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebral Blood Flow (CBF)</measure>
    <time_frame>at 7days, 3 months, 6 months, 12 months or end of trial</time_frame>
    <description>The changes from baseline in CBF measured by arterial spin labeling (ASL) at 7days, 3 months, 6 months, 12 months or end of trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>modified Rankin Scale (mRS)</measure>
    <time_frame>at 7 days, 3 months, 6 months, 12 months or end of trial</time_frame>
    <description>The changes from baseline in modified Rankin Scale (mRS) at 7 days, 3 months, 6 months, 12 months or end of trial. The mRS ranges from 0-6. A mRS of 0-2 is identified as a favourable outcome, and a score of 3-6 as an unfavourable outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>National Institute of Health Stroke Scale (NIHSS)</measure>
    <time_frame>at 7 days, 3 months, 6 months, 12 months or end of trial</time_frame>
    <description>The changes from baseline in National Institute of Health Stroke Scale (NIHSS) at 7 days, 3 months, 6 months, 12 months or end of trial. A total score will be calculated and ranges from 0-42. A NIHSS of 0-14 is identified as a favourable outcome, and a score of 15-42 as an unfavourable outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>modified Barthel Index</measure>
    <time_frame>at 7 days, 3 months, 6 months, 12 months or end of trial</time_frame>
    <description>The changes from baseline in modified Barthel Index at 7 days, 3 months, 6 months, 12 months or end of trial</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Moyamoya Disease</condition>
  <arm_group>
    <arm_group_label>Precision bypass group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Using ICG with Flow800 software and multimodal neuronavigation to choose the recipient vessel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Empirical group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>choosing the recipient vessel by the surgeon's own experience</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Precision bypass group</intervention_name>
    <description>With the brain cortex exposed after craniotomy, an initial ICG fluorescence angiography will be performed. ICG fluorescence angiography using Flow800 software to determine blood flow velocity and cortical perfusion in different candidate receptors. And electromagnetic neuronavigation system is used to evaluate the cerebral flow under different candidate recipient vessels. The treatment planning station will be situated based on the multimodal neuronavigation data. The vessel was chose as the receptor with lower flow velocity and lower cerebral perfusion area to perform anastomosis. Then a direct bypass surgery will be performed just like in the empirical direct bypass surgery group.</description>
    <arm_group_label>Precision bypass group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Independent in activity of daily living(The modified Rankin Scale 0-2)&#xD;
&#xD;
          -  At least one month since the most recent ischemic stroke&#xD;
&#xD;
          -  The neurological deficit must be stable for more than 6 weeks&#xD;
&#xD;
          -  Digital substraction angiography demonstrating progressive stenosis or occlusion in&#xD;
             the terminal portion of the internal carotid artery and/or the initial portion of the&#xD;
             anterior or middle cerebral arteries&#xD;
&#xD;
          -  Digital substraction angiography demonstrating formation of abnormal collateral&#xD;
             networks (moyamoya vessels) at the base of the brain, mainly in the region of thalamus&#xD;
             and basal ganglia&#xD;
&#xD;
          -  Digital substraction angiography demonstrating the vasculopathy appeared unilaterally&#xD;
             or bilaterally&#xD;
&#xD;
          -  Competent to give informed consent&#xD;
&#xD;
          -  Accessible and reliable for follow-up&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other diseases(such as internal carotid artery stenosis, internal carotid artery&#xD;
             dissection, atrial fibrillation, or Intracranial atherosclerosis) probably causing&#xD;
             ischemic strokes&#xD;
&#xD;
          -  Not independent in activity of daily living(The modified Rankin Scale 3-5)&#xD;
&#xD;
          -  Moyamoya syndrome concomitant with other hereditary or autoimmune diseases (Grave's&#xD;
             Disease,Type I Diabetes Mellitus,Type I Neurofibromatosis et al)&#xD;
&#xD;
          -  Patient whose initial onset was marked by ischemia but subsequently suffered from&#xD;
             intracranial hemorrhage&#xD;
&#xD;
          -  Emergent evacuation of intracerebral hematoma damaging superficial temporal artery or&#xD;
             cortical artery&#xD;
&#xD;
          -  Emergent decompressive craniotomy causing automatically developed indirect&#xD;
             revascularization&#xD;
&#xD;
          -  Good collateral networks formed by spontaneous anastomosis between extracranial and&#xD;
             intracranial vessels before surgery&#xD;
&#xD;
          -  Life expectancy&lt;1 years&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Unstable angina or myocardial infarction with recent 6 months&#xD;
&#xD;
          -  Blood coagulation dysfunction&#xD;
&#xD;
          -  Allergic to iodine contrast agent&#xD;
&#xD;
          -  Abnormal liver function(alanine transaminase (ALT) and/or aspartate aminotransferase&#xD;
             (AST)&gt;3 times of normal range)&#xD;
&#xD;
          -  Serum creatinine &gt;3mg/dl&#xD;
&#xD;
          -  Poorly controlled hypertension (systolic BP&gt;160 mmHg,diastolic BP&gt;100 mmHg)&#xD;
&#xD;
          -  Poor glucose control (fasting blood glucose&gt;16.7mmol/l)&#xD;
&#xD;
          -  Concurrent participation in any other interventional clinical trial&#xD;
&#xD;
          -  patients refused to participate in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaolin Chen, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Beijing Tiantan Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Junlin Lu, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Beijing Tiantan Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beijing Tiantan Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>10050</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking University International Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>102200</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Scott RM, Smith ER. Moyamoya disease and moyamoya syndrome. N Engl J Med. 2009 Mar 19;360(12):1226-37. doi: 10.1056/NEJMra0804622. Review.</citation>
    <PMID>19297575</PMID>
  </reference>
  <reference>
    <citation>Kuroda S, Houkin K. Moyamoya disease: current concepts and future perspectives. Lancet Neurol. 2008 Nov;7(11):1056-66. doi: 10.1016/S1474-4422(08)70240-0. Review.</citation>
    <PMID>18940695</PMID>
  </reference>
  <reference>
    <citation>Wakai K, Tamakoshi A, Ikezaki K, Fukui M, Kawamura T, Aoki R, Kojima M, Lin Y, Ohno Y. Epidemiological features of moyamoya disease in Japan: findings from a nationwide survey. Clin Neurol Neurosurg. 1997 Oct;99 Suppl 2:S1-5.</citation>
    <PMID>9409395</PMID>
  </reference>
  <reference>
    <citation>Caldarelli M, Di Rocco C, Gaglini P. Surgical treatment of moyamoya disease in pediatric age. J Neurosurg Sci. 2001 Jun;45(2):83-91.</citation>
    <PMID>11533532</PMID>
  </reference>
  <reference>
    <citation>Suzuki J, Kodama N. Moyamoya disease--a review. Stroke. 1983 Jan-Feb;14(1):104-9.</citation>
    <PMID>6823678</PMID>
  </reference>
  <reference>
    <citation>Baba T, Houkin K, Kuroda S. Novel epidemiological features of moyamoya disease. J Neurol Neurosurg Psychiatry. 2008 Aug;79(8):900-4. Epub 2007 Dec 12.</citation>
    <PMID>18077479</PMID>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>April 21, 2018</study_first_submitted>
  <study_first_submitted_qc>May 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 4, 2018</study_first_posted>
  <last_update_submitted>March 8, 2021</last_update_submitted>
  <last_update_submitted_qc>March 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University International Hospital</investigator_affiliation>
    <investigator_full_name>yuanli Zhaoï¼Œ</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>Moyamoya Disease</keyword>
  <keyword>multimodal neuronavigation</keyword>
  <keyword>flow800</keyword>
  <keyword>direct revascularization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moyamoya Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The study protocol of this study is to be shared</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>from September 1, 2018 to September 1, 2019</ipd_time_frame>
    <ipd_access_criteria>everyone</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

